Big Pharma deals may lie ahead in 2013

01/8/2013 | Bloomberg · PharmaTimes (U.K.)

Pfizer and Merck are among the drugmakers with enough cash on hand to invest $10 billion or more in mergers and acquisitions this year. However, expiring patents on blockbuster drugs, more muscular biotechnology companies and stronger competition might impede Big Pharma's ability to conclude large deals, an Ernst & Young analysis found.

View Full Article in:

Bloomberg · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL